0.6646
3.09%
-0.0319
アフターアワーズ:
.69
0.0254
+3.82%
前日終値:
$0.6965
開ける:
$0.7112
24時間の取引高:
1.14M
Relative Volume:
1.34
時価総額:
$157.26M
収益:
-
当期純損益:
$-179.82M
株価収益率:
-0.3007
EPS:
-2.21
ネットキャッシュフロー:
$-159.16M
1週間 パフォーマンス:
-12.34%
1か月 パフォーマンス:
-26.71%
6か月 パフォーマンス:
+0.75%
1年 パフォーマンス:
-11.13%
Gossamer Bio Inc Stock (GOSS) Company Profile
GOSS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
GOSS | 0.6646 | 157.26M | 0 | -179.82M | -159.16M | -2.21 |
VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-06-25 | 開始されました | Oppenheimer | Outperform |
2024-04-05 | 再開されました | Wedbush | Outperform |
2023-07-27 | ダウングレード | UBS | Buy → Neutral |
2023-03-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2023-03-01 | 開始されました | Guggenheim | Neutral |
2022-12-07 | ダウングレード | Barclays | Overweight → Equal Weight |
2022-12-07 | ダウングレード | JP Morgan | Neutral → Underweight |
2022-12-07 | ダウングレード | SMBC Nikko | Outperform → Neutral |
2022-10-20 | 開始されました | Goldman | Buy |
2022-09-21 | 開始されました | JP Morgan | Neutral |
2022-09-19 | 開始されました | Wedbush | Outperform |
2022-04-18 | 開始されました | Raymond James | Outperform |
2022-04-06 | 開始されました | UBS | Buy |
2022-01-10 | アップグレード | SMBC Nikko | Neutral → Outperform |
2021-11-09 | 再開されました | Cantor Fitzgerald | Overweight |
2021-09-21 | 再開されました | Piper Sandler | Overweight |
2020-06-29 | 開始されました | H.C. Wainwright | Buy |
2020-04-22 | 開始されました | Piper Sandler | Overweight |
2020-02-27 | 開始されました | Barclays | Overweight |
2019-12-03 | 再開されました | BofA/Merrill | Buy |
2019-10-30 | 開始されました | Berenberg | Buy |
2019-03-05 | 開始されました | Barclays | Overweight |
2019-03-05 | 開始されました | BofA/Merrill | Buy |
2019-03-05 | 開始されました | Evercore ISI | Outperform |
2019-03-05 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Gossamer Bio Inc (GOSS) 最新ニュース
All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy - Yahoo Finance
US Bancorp DE Makes New $39,000 Investment in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) - Yahoo Finance
Leerink Partnrs Raises Earnings Estimates for Gossamer Bio - Defense World
After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) - Yahoo Finance
HC Wainwright Increases Earnings Estimates for Gossamer Bio - MarketBeat
FMR LLC's Strategic Acquisition of Gossamer Bio Inc Shares - GuruFocus.com
Industry Analysts Just Made A Sizeable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Revenue Forecasts - Yahoo Finance
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Gossamer Bio Grants 183K Stock Options to New Hires at $0.88 Per Share | GOSS Stock News - StockTitan
Gossamer Bio (NASDAQ:GOSS) Earns Buy Rating from HC Wainwright - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Gossamer Bio Reports Revenue Growth Amid Strategic Collaborations - TipRanks
Gossamer Bio: Q3 Earnings Snapshot - Houston Chronicle
GOSSGossamer Bio, Inc. Latest Stock News & Market Updates - StockTitan
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now - The Manila Times
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Large Decline in Short Interest - Defense World
3 US Penny Stocks With Market Caps Under $900M To Consider - Simply Wall St
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
It makes sense and dollars to buy Gossamer Bio Inc (GOSS) stock - SETE News
Financial Fitness Check: Examining Gossamer Bio Inc (GOSS)’s Key Ratios - The Dwinnex
Gossamer Bio Inc (GOSS) rating initates by Oppenheimer - Knox Daily
Millennium Management LLC Sells 898,042 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Sold by Millennium Management LLC - MarketBeat
The Attractiveness of Investing In Gossamer Bio Inc (GOSS) is Growing - Knox Daily
Investor’s Delight: Gossamer Bio Inc (GOSS) Closes Weak at 1.02, Down -2.86 - The Dwinnex
GOSS underperforms with a -2.86 decrease in share price - US Post News
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Gossamer Bio Inc [NASDAQ: GOSS] Sees Decrease in Stock Value - Knox Daily
Marshall Wace LLP Boosts Position in Gossamer Bio, Inc. (NASDAQ:GOSS) - MarketBeat
Several Insiders Invested In Gossamer Bio Flagging Positive News - Yahoo Finance
Analyzing Northwest Biotherapeutics (OTCMKTS:NWBO) and Gossamer Bio (NASDAQ:GOSS) - Defense World
Navigating GOSS’s Stock Market Maze: Ups and Downs in 2023 - The InvestChronicle
A better buy-in window may exist right now for Gossamer Bio Inc (GOSS) - SETE News
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 5.8% in September - Defense World
Analysts review Gossamer Bio Inc’s rating - Knox Daily
GOSS (Gossamer Bio Inc) has impressive results - US Post News
A company insider recently sold 1,908 shares of Gossamer Bio Inc [GOSS]. Should You Sale? - Knox Daily
GoDaddy (NYSE:GDDY) PT Raised to $185.00 at Barclays - MarketBeat
It makes sense and dollars to buy Gevo Inc (GEVO) stock - SETE News
Gaining Ground: Gossamer Bio Inc (GOSS) Closes Lower at 0.99, Down -0.61 - The Dwinnex
NEA Management Company LLC Buys 2,255,025 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Keeping an Eye on Globus Medical Inc (GMED) After Insider Trading Activity - Knox Daily
Presenting on the Emerging Growth Conference 75 Day 2 on September 26 - GlobeNewswire
Analysts review Godaddy Inc’s rating - Knox Daily
A significant driver of top-line growth: Gossamer Bio Inc (GOSS) - SETE News
Is GlycoMimetics Inc (GLYC) a threat to investors? - US Post News
Globus Medical's (NYSE:GMED) investors will be pleased with their favorable 42% return over the last year - Yahoo Finance
Gossamer Bio Inc (GOSS) 財務データ
収益
当期純利益
現金流量
EPS
Gossamer Bio Inc (GOSS) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Hasnain Faheem | President & CEO |
Jun 21 '24 |
Buy |
0.67 |
372,000 |
250,282 |
5,408,073 |
Giraudo Bryan | COO/CFO |
Jun 18 '24 |
Buy |
0.59 |
100,000 |
59,110 |
480,010 |
Smith Robert Paul JR | Chief Commercial Officer |
Jun 17 '24 |
Buy |
0.60 |
25,000 |
15,050 |
25,000 |
Christian Waage | EVP, Tech Ops and Admin |
Mar 27 '24 |
Sale |
1.16 |
6,430 |
7,430 |
585,934 |
Giraudo Bryan | COO/CFO |
Mar 27 '24 |
Sale |
1.16 |
6,430 |
7,431 |
92,737 |
Hasnain Faheem | President & CEO |
Mar 27 '24 |
Sale |
1.16 |
23,172 |
26,773 |
120,293 |
Aranda Richard | Chief Medical Officer |
Mar 18 '24 |
Sale |
1.33 |
4,018 |
5,342 |
198,799 |
Peterson Caryn | EVP, Regulatory Affairs |
Mar 18 '24 |
Sale |
1.33 |
4,018 |
5,343 |
49,833 |
大文字化:
|
ボリューム (24 時間):